Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second generation) antipsychotic medication. Eligible subjects include men and women, ages 18-75, who have been taking an atypical antipsychotic for at least three months prior to enrollment. Atypical antipsychotics include: clozapine (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole (Abilify), ziprasidone (Geodon), quetiapine (Seroquel), paliperidone (Invega), asenapine (Saphris), iloperidone (Fanapt), and lurasidone (Latuda). Eligible subjects must also have serum triglycerides >200 mg/dl or high cholesterol >250 mg/dl at baseline.

Inclusion criteria

• Female or male patients, 18-75 years of age.
• Serum triglycerides >200 mg/dl or high cholesterol >250 mg/dl
• Current use of an atypical (second-generation) antipsychotic medication - including clozapine (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole (Abilify), ziprasidone (Geodon), quetiapine (Seroquel), paliperidone (Invega) - for at least three months

Exclusion criteria

• Current use of triglyceride or cholesterol-lowering medication other than a statin
• Current use of omega-3 fatty acid supplement
• Intake of fish more than twice per week
• Currently pregnant, or breastfeeding
• Known hypersensitivity or allergy to omega-3 fatty acids (or any fish allergies)
• Current use of anticoagulant medication, except for 1 baby aspirin/day - 81mg (coumadin, heparin, Plavix. etc).
• Consumption of alcohol greater than two drinks per day or active substance abuse
• Any medical condition that would make participation in the study unsafe, as determined by investigator